Kardigan, a heart drug startup run by veterans of MyoKardia, has filed to list on Nasdaq and is pitching roughly a $373 million stock offering that will test whether public investors are really ready to embrace clinical stage biotech again. The South San Francisco company, which has built a data heavy trial platform and licensed programs from MyoKardia and Bristol Myers Squibb, is wagering that three late stage cardiovascular medicines will be enough to win over Wall Street. For locals, it is another high stakes moment for a life sciences crew that helped deliver one of the Bay Area’s biggest biotech exits in recent years.
As reported by Investing.com, Kardigan is marketing about 23.3 million shares at a price range of $14 to $16. That setup would raise roughly $373.3 million and value the company at up to about $1.4 billion at the top of the range. Kardigan has applied to trade under the ticker symbol “KARD” and has lined up J.P. Morgan, Jefferies, Leerink Partners and TD Cowen as joint book running managers.
According to the company's SEC filing, Kardigan was founded in 2023 and is led by CEO Tassos Gianakakos, the former MyoKardia chief. The prospectus shows the company has raised more than $500 million in private financing as it built its Prolaio real world data platform. The registration statement notes that Kardigan has not generated revenue to date and that proceeds from the IPO are earmarked to support ongoing clinical development and for general corporate purposes.
Three late stage bets
Kardigan’s story for investors centers on three cardiovascular programs: danicamtiv for genetic dilated cardiomyopathy, ataciguat for calcific aortic valve stenosis and tonlamarsen for post hospital blood pressure management. The company describes these medicines as late stage and potentially disease modifying, according to Bloomberg Law. Kardigan also highlights Prolaio, an acquired clinical intelligence platform that it says can speed up trial readouts and capture continuous physiologic data from participants.
Why the market is watching
The filing arrives during a tentative thaw in the biotech IPO market, after a series of well funded companies with clearer clinical paths successfully tested public investors, notably Parabilis earlier this year, according to BioPharma Dive. That playbook, in which more mature startups raise large private rounds and only then seek public capital, has made underwriters and crossover investors somewhat more open to clinical stage offerings.
Local coverage of recent IPO wins, such as Avalyn’s eye catching debut that saw its stock pop, has underscored how investors are rewarding companies that can point to clearer trial milestones, as Hoodline reported.
What comes next is largely procedural. Pricing will be set as the offering moves through the syndicate process and the registration becomes effective, and Kardigan’s prospectus says the sale could begin “as soon as practicable” after that authority is granted. For more on the local stakes and deal context, readers can look to reporting by the San Francisco Business Times and to the company’s own disclosures.
-2.webp?w=160&h=400&fit=crop&crop=edges)